Syneron's Innovative Aesthetic Devices Highlighted at The Aesthetic Meeting 2011
09 Mayo 2011 - 12:00PM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic
device company, announced today that several of its products were
highlighted in physician presentations by key opinion leaders in
the aesthetic industry at The Aesthetic Meeting 2011, which is
being held from May 6-11, 2011 at the Boston Convention &
Exhibition Center in Boston, MA.
Louis P. Scafuri, Chief Executive Officer of Syneron, said, "The
Aesthetic Meeting is one of the premiere conferences for our core
physician market and we are pleased that Syneron and Candela
innovative and best-in class products will be featured prominently
throughout the meeting. One of the Company's key initiatives has
been to provide robust clinical evidence supporting the efficacy of
our products and to effectively communicate the strong science that
our technologies are based on. We continue to lead the industry in
this area, as demonstrated by our recent new product launches, many
of which are the topic of presentations at the conference by
thought leading plastic surgeons."
Mr. Scafuri added, "Syneron is ideally positioned to help
plastic surgeons and other aesthetic-focused physicians enhance
their practice by offering products that allow them to address a
wider group of patients with enhanced efficacy, shorter down-time,
and more appealing price points. This includes category-creating
products such as ePrime™, which provides a new dimension in natural
facial enhancement, and eMatrix™, which features Syneron's
pioneering sublative rejuvenation technology for energy-based
facial rejuvenation. These products deliver exceptional results and
patient satisfaction and demonstrate how Syneron is best positioned
to partner with providers to meet evolving expectations with
innovative aesthetic technologies focused on cosmetic medicine and
cosmetic plastic surgery."
Syneron is also featuring its elure™ Advanced Skin Lightening
Technology. elure lightens the skin and provides the pathway for a
meaningful improvement in skin appearance with brighter, more
youthful, healthier skin in just one month with no reports of skin
irritation or other health related risks.
Alan Gold, M.D., F.A.C.S., commented, "I am impressed with the
way elure lightens existing pigment. Other products turn off the
pigment generating mechanism and as pigmented skin migrates for
natural exfoliation we see the lightening effect, but this process
takes months. With elure we see significant benefit as early as a
few weeks."
The Aesthetic Meeting 2011 is organized by the American Society
for Aesthetic Plastic Surgery (ASAPS), which is comprised of over
2,600 plastic surgeons, and the Aesthetic Surgery Education and
Research Foundation (ASERF). More than 1,500 attendees are expected
to attend the meeting, including ASAPS members, members of other
plastic surgery societies, and members of other aesthetic
societies.
Syneron and Candela's family of new products are being featured
at the Company's booth (1039) and were the topic of several
presentations by thought-leading physicians at the meeting. This
included a physician panel presentation titled "Cosmetic Medicine
2011-Achieving Excellent Results" that included:
- Michael I. Kulick, M.D., Board Certified Plastic Surgeon, San
Francisco, CA - Dr. Kulick made a presentation on ePrime, the
Company's recently launched energy-based dermal remodeling
system.
- Hema Sundaram, M.D., Dermatology, Cosmetic & Laser Surgery
Center, Rockville, MD - Dr. Sundaram spoke on eMatrix sublative
rejuvenation, the world's first RF-only technology for energy-based
facial rejuvenation.
- Jeffrey S. Dover, M.D., F.R.C.P.C., SkinCare Physicians of
Chestnut Hill, MA - Dr. Dover made a presentation on the Vbeam
Perfecta, a best in class pulsed dye laser for the treatment of
vascular and pigmented lesions.
Jason Pozner, M.D., F.A.C.S., who is also scheduled to conduct a
workshop covering Syneron products at The Aesthetic Meeting 2011,
commented, "Syneron is a Company that is built on scientific
innovation and clinically proven efficacy. The Company has
established itself as a leader in developing new technologies that
are backed by intensive scientific research, which translates to
exceptional and reliable results for practitioners and their
patients."
About Syneron Medical Ltd. Syneron Medical
Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company
with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and
the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel.
Syneron also has R&D and manufacturing operations in the US.
The Company markets and services and supports its products in 90
countries. It has offices in North America, France, Germany, Italy,
Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and
distributors worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Contacts: Asaf Alperovitz Chief Financial Officer + 972 73 244
2283 Email: Email Contact Nick Laudico Email Contact Zack Kubow
Email Contact The Ruth Group 646-536-7030/7020
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024